文献速递中药与中成药合理使用中医内科

银杏叶提取物对非酒精性脂肪肝大鼠匹伐他汀药代动力学的影响

Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease.
PubMed 文献 · J Ethnopharmacol · 2021-07-27

本研究以高脂饮食诱导的非酒精性脂肪肝(NAFLD)大鼠为模型,考察银杏叶提取物(EGB)活性成分的药代动力学及其对Oatp1b2底物匹伐他汀全身暴露的影响。结果显示NAFLD使匹伐他汀血浆暴露降低约50%,而EGB可剂量依赖性地增加其Cmax和AUC,提示疾病与银杏叶提取物可共同改变肝脏摄取转运体Oatp1b2活性。

要点

  • NAFLD大鼠中匹伐他汀血浆暴露降低约50%,与肝脏Oatp1b2表达增加相关。
  • EGB(3.6–32.4 mg/kg)可剂量依赖性增加匹伐他汀的Cmax和AUC。
  • 临床合用EGB与Oatp1b2底物药物时需关注潜在的草药-疾病-药物相互作用。

核心结论

  • NAFLD与银杏叶提取物可单独或联合改变肝脏摄取转运体Oatp1b2的活性,从而影响底物药物的药代动力学。

研究设计与样本

  • 雄性大鼠以高脂饮食诱导NAFLD模型,考察EGB活性成分药代动力学及匹伐他汀系统暴露。
  • 体外采用hOATP1B1-HEK293细胞评估银杏黄酮醇和萜类内酯对OATP1B1介导摄取的影响。

主要发现

  • NAFLD大鼠口服EGB 3.6–32.4 mg/kg后,银杏内酯和黄酮醇血浆暴露呈剂量依赖性增加。
  • 银杏内酯A、B、C及白果内酯半衰期(2–3 h)短于槲皮素、山柰酚和异鼠李素(约20 h)。
  • NAFLD使匹伐他汀血浆暴露降低约50%,与肝脏Oatp1b2表达增加相关。
  • EGB(3.6→32.4 mg/kg)使匹伐他汀Cmax和AUC0-t分别增加1.8–3.2倍和1.3–3.0倍。
  • 山柰酚和异鼠李素抑制OATP1B1介导的3H-ES摄取,IC50分别为3.28 ± 1.08 μM和46.12 ± 5.25 μM。

临床怎么用

  • 临床使用银杏叶提取物时,应关注与Oatp1b2底物药物(如匹伐他汀)的潜在相互作用。
  • NAFLD患者合用EGB或Oatp1b2底物时,可能需要监测药物暴露变化。

局限性

  • 研究基于高脂饮食诱导的NAFLD大鼠模型,结果外推至临床需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Ginkgo biloba L. is a traditional Chinese medicine for hyper lipaemia. Ginkgo flavonols and terpene lactones are responsible for the lipid-lowering effect in non-alcoholic fatty liver disease (NAFLD). However, the pharmacokinetics of ginkgo flavonols and terpene lactones in NAFLD was not clarified. AIM OF THE STUDY: To investigate the effects of Ginkgo biloba L. leaves extracts (EGB) and NAFLD on hepatocyte organic anion transporting polypeptide (Oatp)1b2, and to assess the pharmacokinetics of EGB active ingredients in NAFLD rats. MATERIALS AND METHODS: Male rats were fed with a high-fat diet to induce NAFLD models. The pharmacokinetic characteristics of EGB active ingredients were studied in NAFLD rats after two or four weeks of treatment with 3.6, 10.8, and 32.4 mg/kg EGB. The effects of NAFLD and EGB were investigated on the systemic exposure of pitavastatin, a probe substrate of Oatp1b2. The inhibitory effects of ginkgo flavonols and terpene lactones on OATP1B1-mediated uptake of 3H-ES were tested in hOATP1B1-HEK293 cells. RESULTS: The plasma exposure of ginkgolides and flavonols in NAFLD rats increased in a dose-dependent manner following oral administration of EGB at 3.6-32.4 mg/kg. The half-lives of ginkgolides A, B, C, and bilobalide (2-3 h) were shorter than quercetin, kaempferol, and isorhamnetin (approximately 20 h). NAFLD reduced the plasma pitavastatin exposure by about 50 % due to the increased Oatp1b2 expression in rat liver. Increased EGB (from 3.6 to 32.4 mg/kg) substantially increased the Cmax and AUC0-t of pitavastatin by 1.8-3.2 and 1.3-3.0 folds, respectively. In hOATP1B1-HEK293 cells, kaempferol and isorhamnetin contributed to the inhibition of OATP1B1-mediated uptake of 3H-ES with IC50 values of 3.28 ± 1.08 μM and 46.12 ± 5.25 μM, respectively. CONCLUSIONS: NAFLD and EGB can alter the activity of hepatic uptake transporter Oatp1b2 individually or in combination. The pharmacokinetic herb-disease-drug interaction found in this research will help inform the clinical administration of EGB or Oatp1b2 substrates.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li Z, Tian S, Wu Z, et al. Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. J Ethnopharmacol. 2021. PMID: 34329714. doi:10.1016/j.jep.2021.114469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。